MARKET

NVCR

NVCR

Novocure
NASDAQ
18.40
-0.08
-0.43%
After Hours: 18.39 -0.01 -0.05% 17:53 07/19 EDT
OPEN
18.57
PREV CLOSE
18.48
HIGH
18.69
LOW
17.88
VOLUME
685.58K
TURNOVER
0
52 WEEK HIGH
42.69
52 WEEK LOW
10.87
MARKET CAP
1.98B
P/E (TTM)
-10.1916
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NVCR last week (0708-0712)?
Weekly Report · 6d ago
Relative Strength Alert For NovoCure
NASDAQ · 07/10 16:42
Weekly Report: what happened at NVCR last week (0701-0705)?
Weekly Report · 07/08 09:21
Breaking Down NovoCure: 4 Analysts Share Their Views
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter. The average price target of $23.0 is an increase of 7.58% from the previous average of $21.38. The company has an average of 12-month price targets of $28.00. Novocure is developing cancer treatments for the treatment of solid tumor cancers.
Benzinga · 07/02 19:01
The Implied Analyst 12-Month Target For IWB
NASDAQ · 07/01 16:26
Weekly Report: what happened at NVCR last week (0624-0628)?
Weekly Report · 07/01 09:21
Weekly Report: what happened at NVCR last week (0617-0621)?
Weekly Report · 06/24 09:22
Weekly Report: what happened at NVCR last week (0610-0614)?
Weekly Report · 06/17 09:21
More
About NVCR
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Webull offers Novocure Ltd stock information, including NASDAQ: NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.